Share-based Payment Arrangement, Expense of Anika Therapeutics, Inc. from 31 Dec 2010 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Anika Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Jun 2025.
  • Anika Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $2,215,000, a 29% decline year-over-year.
  • Anika Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $10,996,000, a 8.7% decline year-over-year.
  • Anika Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $12,158,000, a 10% decline from 2023.
  • Anika Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $13,537,000, a 0.54% decline from 2022.
  • Anika Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $13,611,000, a 23% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Anika Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $10,996,000 $2,215,000 -$903,000 -29% 01 Apr 2025 30 Jun 2025 10-Q 05 Nov 2025 2025 Q3
Q1 2025 $11,899,000 $2,995,000 -$259,000 -8% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $12,158,000 $2,392,000 +$283,000 +13% 01 Oct 2024 31 Dec 2024 10-K 17 Mar 2025 2024 FY
Q3 2024 $11,875,000 $3,394,000 -$167,000 -4.7% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2024 2024 Q3
Q2 2024 $12,042,000 $3,118,000 -$1,032,000 -25% 01 Apr 2024 30 Jun 2024 10-Q 05 Nov 2025 2025 Q3
Q1 2024 $13,074,000 $3,254,000 -$463,000 -12% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 $13,537,000 $2,109,000 -$1,000,000 -32% 01 Oct 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
Q3 2023 $14,537,000 $3,561,000 -$315,000 -8.1% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $14,852,000 $4,150,000 +$69,000 +1.7% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $14,783,000 $3,717,000 +$1,172,000 +46% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $13,611,000 $3,109,000 -$57,000 -1.8% 01 Oct 2022 31 Dec 2022 10-K 17 Mar 2025 2024 FY
Q3 2022 $13,668,000 $3,876,000 +$1,013,000 +35% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $12,655,000 $4,081,000 +$1,284,000 +46% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $11,371,000 $2,545,000 +$286,000 +13% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $11,085,000 $3,166,000 +$1,733,000 +121% 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2024 2023 FY
Q3 2021 $9,352,000 $2,863,000 +$943,000 +49% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $8,409,000 $2,797,000 +$557,000 +25% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $7,852,000 $2,259,000 +$2,466,000 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $5,386,000 $1,433,000 -$514,000 -26% 01 Oct 2020 31 Dec 2020 10-K 16 Mar 2023 2022 FY
Q3 2020 $5,900,000 $1,920,000 +$609,000 +46% 01 Jul 2020 30 Sep 2020 10-Q 05 Nov 2021 2021 Q3
Q2 2020 $5,291,000 $2,240,000 +$797,000 +55% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021 2021 Q2
Q1 2020 $4,494,000 $207,000 -$1,593,000 -115% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $6,087,000 $1,947,000 +$965,000 +98% 01 Oct 2019 31 Dec 2019 10-K 11 Mar 2022 2021 FY
Q3 2019 $5,122,000 $1,311,000 +$134,000 +11% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $4,988,000 $1,443,000 +$121,000 +9.2% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $4,867,000 $1,386,000 -$6,179,000 -82% 01 Jan 2019 31 Mar 2019 10-Q 22 May 2020 2020 Q1
Q4 2018 $11,046,000 $982,000 -$885,000 -47% 01 Oct 2018 31 Dec 2018 10-K/A 26 Apr 2021 2020 FY
Q3 2018 $11,931,000 $1,177,000 -$297,000 -20% 01 Jul 2018 30 Sep 2018 10-Q 28 Oct 2019 2019 Q3
Q2 2018 $12,228,000 $1,322,000 +$38,000 +3% 01 Apr 2018 30 Jun 2018 10-Q 26 Jul 2019 2019 Q2
Q1 2018 $12,190,000 $7,565,000 +$6,383,000 +540% 01 Jan 2018 31 Mar 2018 10-Q 06 May 2019 2019 Q1
Q4 2017 $5,807,000 $1,867,000 +$750,000 +67% 01 Oct 2017 31 Dec 2017 10-K 06 Mar 2020 2019 FY
Q3 2017 $5,057,000 $1,474,000 +$677,000 +85% 01 Jul 2017 30 Sep 2017 10-Q 26 Oct 2018 2018 Q3
Q2 2017 $4,380,000 $1,284,000 +$623,000 +94% 01 Apr 2017 30 Jun 2017 10-Q 31 Jul 2018 2018 Q2
Q1 2017 $3,757,000 $1,182,000 +$365,000 +45% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $3,392,000 $1,117,000 +$454,391 +69% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
Q3 2016 $2,937,609 $797,000 +$298,558 +60% 01 Jul 2016 30 Sep 2016 10-Q 27 Oct 2017 2017 Q3
Q2 2016 $2,639,051 $661,000 +$151,648 +30% 01 Apr 2016 30 Jun 2016 10-Q 28 Jul 2017 2017 Q2
Q1 2016 $2,487,403 $817,000 +$262,403 +47% 01 Jan 2016 31 Mar 2016 10-Q 04 May 2017 2017 Q1
Q4 2015 $2,225,000 $662,609 +$251,970 +61% 01 Oct 2015 31 Dec 2015 10-K 27 Feb 2018 2017 FY
Q3 2015 $1,973,030 $498,442 +$107,864 +28% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2015 2015 Q3
Q2 2015 $1,865,166 $509,352 +$131,392 +35% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2015 2015 Q2
Q1 2015 $1,733,774 $554,597 +$126,774 +30% 01 Jan 2015 31 Mar 2015 10-Q 04 May 2015 2015 Q1
Q4 2014 $1,607,000 $410,639 +$267,568 +187% 01 Oct 2014 31 Dec 2014 10-K 24 Feb 2017 2016 FY
Q3 2014 $1,339,432 $390,578 +$21,975 +6% 01 Jul 2014 30 Sep 2014 10-Q 03 Nov 2015 2015 Q3
Q2 2014 $1,317,457 $377,960 +$12,593 +3.4% 01 Apr 2014 30 Jun 2014 10-Q 04 Aug 2015 2015 Q2
Q1 2014 $1,304,864 $427,823 +$4,864 +1.2% 01 Jan 2014 31 Mar 2014 10-Q 04 May 2015 2015 Q1
Q4 2013 $1,300,000 $143,071 -$94,125 -40% 01 Oct 2013 31 Dec 2013 10-K 10 Mar 2016 2015 FY
Q3 2013 $1,394,125 $368,603 +$87,673 +31% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $1,306,452 $365,367 +$52,804 +17% 01 Apr 2013 30 Jun 2013 10-Q 04 Aug 2014 2014 Q2
Q1 2013 $1,253,648 $422,959 +$102,449 +32% 01 Jan 2013 31 Mar 2013 10-Q 05 May 2014 2014 Q1
Q4 2012 $1,151,199 $237,196 01 Oct 2012 31 Dec 2012 10-K 13 Mar 2015 2014 FY
Q3 2012 $280,930 -$38,382 -12% 01 Jul 2012 30 Sep 2012 10-Q 05 Nov 2013 2013 Q3
Q2 2012 $312,563 +$30,531 +11% 01 Apr 2012 30 Jun 2012 10-Q 06 Aug 2013 2013 Q2
Q1 2012 $320,510 01 Jan 2012 31 Mar 2012 10-Q 06 May 2013 2013 Q1
Q3 2011 $319,312 01 Jul 2011 30 Sep 2011 10-Q 08 Nov 2012 2012 Q3
Q2 2011 $282,032 01 Apr 2011 30 Jun 2011 10-Q 07 Aug 2012 2012 Q2

Anika Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $12,158,000 -$1,379,000 -10% 01 Jan 2024 31 Dec 2024 10-K 17 Mar 2025 2024 FY
2023 $13,537,000 -$74,000 -0.54% 01 Jan 2023 31 Dec 2023 10-K 17 Mar 2025 2024 FY
2022 $13,611,000 +$2,526,000 +23% 01 Jan 2022 31 Dec 2022 10-K 17 Mar 2025 2024 FY
2021 $11,085,000 +$5,699,000 +106% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2024 2023 FY
2020 $5,386,000 -$701,000 -12% 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2023 2022 FY
2019 $6,087,000 -$4,959,000 -45% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2022 2021 FY
2018 $11,046,000 +$5,239,000 +90% 01 Jan 2018 31 Dec 2018 10-K/A 26 Apr 2021 2020 FY
2017 $5,807,000 +$2,415,000 +71% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2020 2019 FY
2016 $3,392,000 +$1,167,000 +52% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $2,225,000 +$618,000 +38% 01 Jan 2015 31 Dec 2015 10-K 27 Feb 2018 2017 FY
2014 $1,607,000 +$307,000 +24% 01 Jan 2014 31 Dec 2014 10-K 24 Feb 2017 2016 FY
2013 $1,300,000 +$148,801 +13% 01 Jan 2013 31 Dec 2013 10-K 10 Mar 2016 2015 FY
2012 $1,151,199 -$39,498 -3.3% 01 Jan 2012 31 Dec 2012 10-K 13 Mar 2015 2014 FY
2011 $1,190,697 +$88,080 +8% 01 Jan 2011 31 Dec 2011 10-K 14 Mar 2013 2012 FY
2010 $1,102,617 01 Jan 2010 31 Dec 2010 10-K 14 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.